24H|Vanda Pharmaceuticals Jumps 20%; Sable Offshore Gains 5%; Nike up 2%

Tiger Newspress
2025/12/31

Vanda Pharmaceuticals stocks jumped 20% in overnight trading after the company said on Tuesday its drug for the prevention of motion-induced vomiting was approved by the U.S. health regulator, becoming the first treatment for the condition to receive the nod in more than 40 years.

The company expects to launch the drug, Nereus, in the coming months.

Sable Offshore Corp. stock rose 5% in overnight trading after Jefferies maintained its Buy rating and $19.00 price target on Sable Offshore stock following recent regulatory developments and legal challenges for the company’s pipeline project.

The Pipeline and Hazardous Materials Safety Administration (PHMSA) issued an Emergency Special Permit approving Sable’s pipeline on December 23, marking a significant regulatory milestone for the company.

This approval was quickly followed by a lawsuit filed by non-governmental organizations with the 9th Circuit Court of Appeals, creating new uncertainty for the project’s timeline and implementation.

Legal briefings related to the case are due December 30 and 31, with questions remaining about whether the court proceedings will result in an injunction that could further delay the pipeline.

Nike stock rose 2% in overnight trading.

免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。

熱議股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10